Beyond Air, Inc. (XAIR)
NASDAQ: XAIR · Real-Time Price · USD
0.4128
-0.0373 (-8.29%)
At close: Jun 5, 2026, 4:00 PM EDT
0.4100
-0.0028 (-0.68%)
After-hours: Jun 5, 2026, 7:54 PM EDT
Beyond Air Revenue
Beyond Air had revenue of $2.19M in the quarter ending December 31, 2025, with 104.66% growth. This brings the company's revenue in the last twelve months to $6.92M, up 129.04% year-over-year. In the fiscal year ending March 31, 2025, Beyond Air had annual revenue of $3.71M with 219.67% growth.
Revenue (ttm)
$6.92M
Revenue Growth
+129.04%
P/S Ratio
0.79
Revenue / Employee
$113,508
Employees
61
Market Cap
5.45M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.71M | 2.55M | 219.67% |
| Mar 31, 2024 | 1.16M | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | 873.00K | -517.10K | -37.20% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vivos Therapeutics | 19.57M |
| Tenon Medical | 4.60M |
| Biomerica | 4.33M |
| Intelligent Bio Solutions | 3.91M |
| ENvue Medical | 2.18M |
| Sintx Technologies | 1.03M |
| iTonic Holdings | 523.03K |
| HeartSciences | 8.67K |
XAIR News
- 6 days ago - Beyond Air receives Nasdaq hearing panel decision granting continued listing - TheFly
- 6 days ago - Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing - GlobeNewsWire
- 4 weeks ago - Beyond Air Proxy statement: Proxy filing - Filings
- 6 weeks ago - Beyond Air Proxy statement: Proxy filing - Filings
- 6 weeks ago - Beyond Air’s Beyond Cancer reports updated data from Phase 1 UNO trial - TheFly
- 6 weeks ago - Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026 - GlobeNewsWire
- 7 weeks ago - Beyond Air to Participate in the D. Boral Capital Global Conference 2026 - GlobeNewsWire
- 2 months ago - Beyond Air CEO Steve Lisi resigns, Robert Goodman succeeds - TheFly